EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, CSL's Enterprise Value is $96,966 Mil.
CSL's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $3,507 Mil. Therefore, CSL's EV-to-EBIT for today is 27.65.
The historical rank and industry rank for CSL's EV-to-EBIT or its related term are showing as below:
CSLLY'
s EV-to-EBIT Range Over the Past 10 Years
Min: 18.32 Med: 29.93 Max: 43.72
Current: 27.69
During the past 13 years, the highest EV-to-EBIT of CSL was 43.72. The lowest was 18.32. And the median was 29.93.
CSLLY's EV-to-EBIT is ranked worse than 76.71% of 438
companies
in the Biotechnology industry
Industry Median: 8.725
vs CSLLY: 27.69
The historical data trend for CSL's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, CSL's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CSL's EV-to-EBIT Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CSL's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where CSL's EV-to-EBIT falls into.
CSL's current Enterprise Value is $96,966 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. CSL's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $3,507 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSL (OTCPK:CSLLY) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
CSL's Enterprise Value for the quarter that ended in Dec. 2023 was $106,959 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. CSL's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $3,507 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSL EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of CSL's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
CSL is one of the largest global biotech companies and has two main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders and neurological indications. Seqirus is now the world's second largest influenza vaccination business and was acquired in fiscal 2015. CSL has a strong R&D track record, and the product portfolio and pipeline include non-plasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CSLLY has been successfully added to your 